Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market

Report ID : 1297 | Published : 2022-07-06 | Pages: | Format: PDF/EXCEL

The market size of the Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market in the year 2021 is valued at 4.80 billion and is predicted to reach 23.06 billion by the year 2030 at an 19.2% CAGR during the forecast period.

Circulating cell-free DNA is defined as DNA fragments released in the bloodstream for essential and chronic disorders. ccfDNA, also known as circulating DNA (ctDNA), has recently gained popularity as a non-invasive illness biomarker. The scientific community's interest in therapeutic applications of ctDNA continues to grow at an exponential rate, fueling its attractiveness as a viable target in a wide range of study domains. One of the primary drivers of the Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market is the growing concern for early cancer detection. Other drivers include the success of NIPTs, increased cancer prevalence, and an increase in research and development initiatives to investigate the usefulness of circulating biomarkers in disease diagnosis. Furthermore, advances in molecular technology are promoting the exploration of cfDNA as a possible tool for the creation of minimally invasive diagnostics. The use of cfDNA-based diagnostics enhances both informed clinical decision-making and patient outcomes.

However, lack of standardization, poor reimbursement policies, and legal and regulatory restrictions are among the factors impeding market expansion. The dearth of awareness among people in underdeveloped nations is also hindering market expansion.

Market Segmentation:

The Circulating Cell-Free DNA (ccfDNA) Diagnostics market is segmented on the basis of components, Application and end-users. Based on Application, the market is segmented into Non-invasive Prenatal Testing, Cancer Diagnostics, and Others. Based on End-Use, the market is segmented into Hospitals & Prenatal Clinics, Diagnostic Centers, Academic & Government Institutes, Biotechnology & Pharmaceutical Companies.

Based on Non-Invasive Prenatal Testing, the Virtual Reality Headset segment is accounted as a major contributor in the Circulating Cell-Free DNA (ccfDNA) Diagnostics market.

The market for circulating cell-free DNA (ccfDNA) diagnostics is expected to be dominated by non-invasive prenatal testing in terms of revenue. The dominance of this market has been aided by the popularity of non-invasive tests based on cfDNA. Furthermore, the segment is being driven by increased medical coverage for NIPTs. A non-invasive DNA testing process without the hazards associated with amniocentesis or CVS (chorionic villus sample). One of the major aspects driving this segment's revenue growth is increasing knowledge of the procedure's benefits. On the other hand, the category for cancer diagnostics is anticipated to develop the fastest. The main engine of segment expansion is rising investment in the creation of liquid biopsies.

 

Hospital & Prenatal Clinics segment witnessed growth at a rapid rate

The hospitals & prenatal clinics segment is anticipated to gain the major share of the global circulating cell-free DNA (ccfDNA) diagnostics market in the forecast period. The public's understanding and acceptance of non-invasive prenatal DNA screening is growing, which has boosted this sector's income flow. Hospitals & prenatal clinics remain the leading end-users of the market due to the benefits of NIPTs, such as early risk diagnosis of chromosomal defects like down syndrome and trisomy utilizing NIPTs. However, the fastest expanding end-user of this industry is emerging to be the biotechnology and pharmaceutical industries. The primary driver of this category is the recent approval of companion diagnostics.

The North America Circulating Cell-Free DNA (ccfDNA) Diagnostics market holds a significant revenue share in the region.

The North America Circulating Cell-Free DNA (ccfDNA) Diagnostics market is likely to register a significant revenue share. Countries like Canada and the United States contribute the most to it. Because of these areas' growing economies, improved healthcare infrastructure, and rising illness prevalence, The promise of the cell-free DNA testing business has enticed numerous biotechnology and pharmaceutical companies to acquire other large companies or establish new tests. Increased rates of disorders such as chromosomal abnormalities owing to high maternal age, changing lifestyle, bad diet habits, and rising cancer prevalence, as well as increasing healthcare spending and awareness, are driving the cell-free DNA market in this area.

Competitive Landscape

The key players in the Circulating Cell-Free DNA (ccfDNA) Diagnostics market have shifted their focus towards bio-based components for product manufacturing and are initiating significant strategies such as mergers, acquisitions, and joint ventures of major and domestic players to enhance product portfolio and strengthen their market footprint across the globe. Some of the major key players in the Circulating Cell-Free DNA (ccfDNA) Diagnostics market are Hoffmann-La Roche, Natera Inc., Illumina Inc., Agena Bioscience, Paragon Genomics, Thermo Fisher Scientific, Bio-Rad Laboratories, Lucence Health, and Eurofins.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Circulating Cell-Free DNA (ccfDNA) Diagnostics Market Snapshot

Chapter 4. Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Application Estimates & Trend Analysis

5.1. By Application & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Application:

5.2.1. Non-invasive Prenatal Testing

5.2.2. Cancer Diagnostics

5.2.3. Others

Chapter 6. Market Segmentation 2: By End-use Estimates & Trend Analysis

6.1. By End-use & Market Share, 2020 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By End-use:

6.2.1. Hospitals & Prenatal Clinics

6.2.2. Diagnostic Centers

6.2.3. Academic & Government Institutes

6.2.4. Biotechnology & Pharmaceutical Companies 

Chapter 7. Circulating Cell-Free DNA (ccfDNA) Diagnostics Market Segmentation 4: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Circulating Cell-Free DNA (ccfDNA) Diagnostics Market revenue (US$ Million) estimates and forecasts By Application, 2020-2030

7.1.2. North America Circulating Cell-Free DNA (ccfDNA) Diagnostics Market revenue (US$ Million) estimates and forecasts By End-use, 2020-2030

7.1.3. North America Circulating Cell-Free DNA (ccfDNA) Diagnostics Market revenue (US$ Million) estimates and forecasts by country, 2020-2030

7.2. Europe

7.2.1. Europe Circulating Cell-Free DNA (ccfDNA) Diagnostics Market revenue (US$ Million) By Application, 2020-2030

7.2.2. Europe Circulating Cell-Free DNA (ccfDNA) Diagnostics Market revenue (US$ Million) By End-use, 2020-2030

7.2.3. Europe Circulating Cell-Free DNA (ccfDNA) Diagnostics Market revenue (US$ Million) by country, 2020-2030

7.3. Asia Pacific

7.3.1. Asia Pacific Circulating Cell-Free DNA (ccfDNA) Diagnostics Market revenue (US$ Million) By Application, 2020-2030

7.3.2. Asia Pacific Circulating Cell-Free DNA (ccfDNA) Diagnostics Market revenue (US$ Million) By End-use, 2020-2030

7.3.3. Asia Pacific Circulating Cell-Free DNA (ccfDNA) Diagnostics Market revenue (US$ Million) by country, 2020-2030

7.4. Latin America

7.4.1. Latin America Circulating Cell-Free DNA (ccfDNA) Diagnostics Market revenue (US$ Million) By Application, (US$ Million)

7.4.2. Latin America Circulating Cell-Free DNA (ccfDNA) Diagnostics Market revenue (US$ Million) By End-use, (US$ Million)

7.4.3. Latin America Circulating Cell-Free DNA (ccfDNA) Diagnostics Market revenue (US$ Million) by country, 2020-2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa Circulating Cell-Free DNA (ccfDNA) Diagnostics Market revenue (US$ Million) By Application, (US$ Million)

7.5.2. Middle East & Africa Circulating Cell-Free DNA (ccfDNA) Diagnostics Market revenue (US$ Million) By End-use, (US$ Million)

7.5.3. Middle East & Africa Circulating Cell-Free DNA (ccfDNA) Diagnostics Market revenue (US$ Million) by country, 2020-2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Hoffmann-La Roche

8.2.2. Natera Inc.

8.2.3. Illumina Inc.

8.2.4. Agena Bioscience

8.2.5. Paragon Genomics

8.2.6. Thermo Fisher Scientific

8.2.7. Bio-Rad Laboratories

8.2.8. Lucence Health

8.2.9. Eurofins

8.2.10. Other Prominent Players

Segmentation of Circulating Cell-Free DNA (ccfDNA) Diagnostics Market-

By Application

  • Non-invasive Prenatal Testing
  • Cancer Diagnostics
  • Others

By End-Use

  • Hospitals & Prenatal Clinics
  • Diagnostic Centers
  • Academic & Government Institutes
  • Biotechnology & Pharmaceutical Companies

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?

Frequently Asked Questions

Who are the Key Players in the Circulating Cell-Free DNA (ccfDNA) Diagnostics Market?

Market in the year 2021 is valued at 4.80 billion

predicted to reach 23.06 billion by the year 2030 at an 19.2% CAGR during the forecast period.

Our Clients